Showing 6361-6370 of 9147 results for "".
- European Commission Grants Conditional Approval to Erivedgehttps://practicaldermatology.com/news/20130716-european_commission_grants_conditional_approval_to_erivedge/2459497/The European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. The Commission granted the conditional approval based upon t
- Sensus Healthcare Appoints Dr. Clay Cockerell as Medical Directorhttps://practicaldermatology.com/news/20130716-sensus_healthcare_appoints_dr_clay_cockerell_as_medical_director/2459498/Clay Cockerell, MD has been appointed Medical Director for the medical device company Sensus Healthcare. Dr. Cockerell will lead the Medical Advisory Board as the company continues to provide technology for non-invasive skin cancer treatment for non-melanoma skin cancer as well as treatment for kelo
- ExtendCredit Launches “Cosmetic Credit Plans”https://practicaldermatology.com/news/20130702-extendcredit_launches_cosmetic_credit_plans/2459505/“Cosmetic Credit Plans” is a fully automated, customizable in-house financing software solution created specifically for the cosmetic surgery industry, offered by ExtendCredit. The software enables cosmetic surgeons to offer their own financi
- DBV Technologies Presents Breakthrough Data at EAACI-WAO Congresshttps://practicaldermatology.com/news/20130702-dbv_technologies_presents_breakthrough_data_at_eaaci-wao_congress/2459506/DBV Technologies presented six clinical and preclinical presentations on Epicutaneaous Immunotherapy (EPIT) at the European Academy of Allergy & Clinical Immunology & World Allergy Organization & World Allergy & Asthma Congress (EAACI-WAO) in Milan, Italy. DBV's Viaskin technology was highlighted in
- MiraConnect Lets Candidates Interact with miraDry Treatment Veteranshttps://practicaldermatology.com/news/20130625-miraconnect_lets_candidates_interact_with_miradry_treatment_veterans/2459509/Offering an opportunity for interested to learn more about microwave-based therapy for hyperhidrosis, the miraConnect program from Miramar Labs enables treatment candidates to speak one-on-one with patients who have undergone the procedu
- Geneticists Research Cleft Palate and Skin Deformitieshttps://practicaldermatology.com/news/20130614-geneticists_research_cleft_palate_and_skin_deformities/2459514/Scientists at Cold Spring Harbor Laboratory (CSHL) solved the mystery of why some infants are born with cleft palate and major deformities of the skin and limbs, while other infants with the same genetic mutation bear little or no sign of the illness, called Ectodactyly, Ectodermal dysplasia, Clefti
- Steve Perry Undergoes Cancer Surgeryhttps://practicaldermatology.com/news/20130611-steve_perry_undergoes_cancer_surgery/2459515/Former Journey singer Steve Perry had a cancerous mole on his right cheek removed recently. Test results found it positive for melanoma. Perry had to undergo two procedures to rid his skin of all of the cancer cells, according to his physicians, and no further treatment will be necessary.
- Avène SPF Awarded Skin Cancer Foundation Seal Of Recommendationhttps://practicaldermatology.com/news/20130611-avne_spf_awarded_skin_cancer_foundation_seal_of_recommendation/2459517/The Skin Cancer Foundation approved Avène High Protection Tinted Compact SPF 50 in both shades (Beige and Honey) to carry The Skin Cancer Foundation Active Seal of Recommendation. The coveted Seal signifies that these products have
- Suneva Selects Quinnova to Co-promote ReFissahttps://practicaldermatology.com/news/20130610-suneva_selects_quinnova_to_co-promote_refissa/2459520/Suneva Medical, Inc. selected Quinnova Pharmaceuticals, LLC to co-promote ReFissa. ReFissa is the only FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.
- Results of SB204 Clinical Study in Acne Releasedhttps://practicaldermatology.com/news/20130605-results_of_sb204_clinical_study_in_acne_released/2459523/Nitric oxide releasing drug candidate SB204 reduces colonization of the acne-causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers, according to a recent trial. This study, in combination with Novan Therapeutics' earlier findings regarding sebum production, suggests t